All eyes on data on Biogen’s tau therapy
Biogen’s experimental anti-tau therapy, Diranersen, reports slowed cognitive decline in early Alzheimer's disease patients during Phase 2 clinical trials.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Biogen presented Phase 2 CELIA study results at the Alzheimer’s Association International Conference (AAIC). The data indicates that the investigational anti-tau oligonucleotide, Diranersen, achieved robust tau reduction and slowed cognitive decline in individuals with early-stage Alzheimer’s disease.
Coverage from STAT, Fierce Biotech, AP News, and Biogen highlights that the observed rates of cognitive slowing are comparable to currently approved Alzheimer's therapies. Reports emphasize the significance of the data as the pharmaceutical industry seeks new therapeutic approaches for the condition.
Future updates are expected to center on the drug's path toward a pivotal development push. Coverage does not yet specify a timeline for further regulatory filings or late-stage trial designs.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What is the name of the drug being studied?
The experimental anti-tau oligonucleotide is called Diranersen.
Where were these findings presented?
The results were presented at the Alzheimer’s Association International Conference (AAIC).
How does the drug's performance compare to existing options?
According to STAT, the drug slowed cognitive decline at rates on par with therapies that are already approved.
Coverage (5)
- AAIC: Biogen bolsters hopes for Alzheimer's pivotal push as anti-tau oligo slows cognitive decline Fierce Biotech · 1d ago
- Biogen Alzheimer's drug slowed decline at rates on par with approved therapies, study shows STAT · 1d ago
- An experimental Alzheimer's drug shows some promise as researchers hunt new approaches AP News · 1d ago
- Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease Biogen · 1d ago
- All eyes on data on Biogen’s tau therapy STAT · 1d ago
Topics
Related trends
FDA releases 14 drug rejection letters after 3-month pause
The FDA has resumed issuing drug rejection letters, releasing 14 new Complete Response Letters following a three-month period of silence.
A Human-Safe Drug Reduces Multiple Signs of Alzheimer's in Mice
A preclinical study highlights the potential of drug candidate KCL-286 to address multiple markers of Alzheimer’s disease in mice.
Why your health plan doesn’t cover GLP-1s, according to a top insurance exec
Employer health plan coverage for GLP-1 weight-loss medications is evolving as access hurdles and alternative payment strategies emerge.
2 common drugs may offer short-term improvements in long-COVID-related fatigue
Two widely available drugs show *limited* promise for long-COVID fatigue—raising cautious hope for millions.
Scientists Discover a Sign of Dementia up to 15 Years Before Diagnosis
Researchers identify potential blood-based biomarkers that could detect dementia risk *decades* before symptoms emerge
Alcohol Alters Brain Flexibility Based on Hidden Dementia Markings
New research suggests alcohol consumption affects brain plasticity and Alzheimer's-related circuits differently depending on underlying brain pathology.